High frequency of chromosome 9 deletion in ovarian cancer: Evidence for three tumour-suppressor loci

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 420-423

  Devlin, J ^a   Elder, P A ^a   Gabra, H ^b   Steel, C M ^c   Knowles, M A ^a  

^a MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Chromosome 9; Deletion mapping; Ovarian cancer; Tumour suppressor

Indexed keywords

CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR;

ARTICLE; BASAL CELL NEVUS SYNDROME; CANCER GENETICS; CHROMOSOME 9; CHROMOSOME 9P; CHROMOSOME 9Q; CHROMOSOME DELETION; CLINICAL ARTICLE; FEMALE; GENE LOSS; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MARKER GENE; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0030020856     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.75     Document Type: Article

References (21)

1. CAIRNS P, TORINO K, EBY Y AND SIDRANSKY D. (1994). Homozygous deletions of 9p21 in primary human bladder tumours detected by comparative multiplex polymerase chain reaction. Cancer Res., 54, 1422-1424.
2. CAIRNS P, TORINO K, EBY Y AND SIDRANSKY D. (1995). Localisation of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res., 55, 224-227.
3. CARBONARA C, LONGA L, GROSSO E, BORRONE C, GRAZIA-GARRE M, BRISIGOTTI M AND MIGONE N. (1994). 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum. Mol. Genet., 3, 1829-1832.
4. CHENEVIX-TRENCH G, KERR J, FRIEDLANDER M, HURST T, SANDERSON B, COGLAN M, WARD B, LEARY J AND KHOO S-K. (1994). Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am. J. Hum. Genet., 55, 143-149.
5. CLIBY W, RITLAND S, HARTMANN L, DOBSON M, HALLING KC, KEENEY G, PODRATZ KC AND JENKINS RB. (1993). Human epithelial ovarian cancer allelotype. Cancer Res., 53, 2393-2398.
6. DEVLIN J, KEEN AJ AND KNOWLES MA. (1994). Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2 cM of IFNA. Oncogene, 9, 2757-2760.
7. ECCLES D, CRANSTON G, STEEL CM, NAKAMURA Y AND LEONARD RCF. (1990). Allelelosses on chromsome 17 in human epithelial cancer. Oncogene, 5, 1599-1601.
8. FOUNTAIN JW, KARAYIORGOU M, ERNSTOFF MS, KIRKWOOD JM, VLOCK DR, TITUS-ERNSTOFF L, BOUCHARD B, VIJAYASARDHI S AND DRACOPOLI NC. (1992). Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl Acad. Sci. USA, 89, 10557-10561.
9. HABUCI T, DEVLIN J, ELDER PA AND KNOWLES MA. (1995). Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene, 11, 1671-1674.
10. KAMB A, GRUIS NA, WEAVER-FELDHAUS J, LIU Q, HARSHMAN K, TAVTIGIAN SV, STOCKERT E, DAY RS, JOHNSON BE AND SKOLNICK MH. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
11. KEEN AJ AND KNOWLES MA. (1994). Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene, 9, 2083-2088.
12. MERLO A, GABRIELSON E, MABRY M, VOLLMER R, BAYLIN SB AND SIDRANSKY D. (1994). Homozygous deletion on chromsome 9p and loss of heterozygosity on 9q, 6p and 6q in primary human small cell lung cancer. Cancer Res., 54, 2322-2326.
13. NOBORI T, MIURA K, WU DJ, LOIS A, TAKABAYASHI K AND CARSON DA. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
14. OSBORNE RJ AND LEECH V. (1994a). Polymerase chain reaction allelotyping of human ovarian cancer. Br. J. Cancer, 69, 429-438.
15. OSBORNE RJ AND LEECH V. (1994b). Chromosome 9q deletion mapping in epithelial ovarian cancer. Proc. Am. Assoc. Cancer Research, 35, 601.
16. POVEY S, ARMOUR J, FARNDON P, HAINES JL, KNOWLES MA, OLOPADE F, PILZ A, WHITE J, MEMBERS OF THE UTAH GENOME CENTER GENETIC MARKER AND MAPPING GROUP AND KWIATKOWSKI DJ. (1994). Report on the third international workshop on chromosome 9. Ann. Hum. Genet., 58, 177-250.
17. QUINN AG, SIKKINK S AND REES JL. (1994). Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers. Genes, Chrom. Cancer, 11, 222-225.
18. SCHULTZ DC, VANDERVEER L, BUETOW KH, BOENTE MP, OZOLS RF, HAMILTON TC AND GODWIN AK. (1995). Characterisation of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res., 55, 2150-2157.
19. SHANLEY SM, DAWKINS H, WAINWRIGHT BJ, WICKING C, HEENAN P, ELDON M, SEARLE J AND CHENEVIX-TRENCH G. (1995). Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas. Hum. Mol. Genet., 4, 129-133.
20. VAN DER RIET P, NAWROZ H, HRUBAN RH, CORIO R, TOKINO K, KOCH W AND SIDRANSKY D. (1994). Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res., 54, 1156-1158.
21. WILLIAMSON MP, ELDER PA, SHAW ME, DEVLIN J AND KNOWLES MA. (1995). p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum. Mol. Genet., 4, 1569-1577.